Zoloft®

Log-in
Register

Therapeutic Areas
Viatris Medicines
- Register

Viatris Medicines
Zoloft^®

Zoloft^®

<

>

Zoloft^®

Mode of Action

Mechanism of Action

Significant improvements of depressive symptoms with ZOLOFT® vs placebo at Week 8, as measured by HAM-D17

EFFICACY

SAFETY & TOLERABILITY

SAFETY & TOLERABILITY

DOSING & ADMINISTRATION

Posology & Method of Administration

Treatment Guidelines

Treatment Guidelines

Clinical Information

Clinical Information

Patient Profiles

Celebrex Safety

Prof Nemeroff Video - MDD in chronic conditions

Celebrex Safety

Brain Circuits - Personalized Approach to a Patient

Celebrex Safety

Use of sertraline in depression in women in childbearing age video

Celebrex Safety

Treatment goals in MDD and anxiety-Prof Correll Video

Follow Us

Contact Us
Adverse Events Reporting
Cookie Notice
Medical Information
Privacy Policy
Terms and Conditions

Copyright © 2023 Viatris Middle East FZ-LLC FZ LLC. All rights reserved.

The product information provided in this site is intended only for Healthcare Professionals of Gulf Countries*. The products discussed herein may have different product labeling in different countries.

The information provided on this website is intended only for healthcare professionals of Gulf Countries*

*UAE, Bahrain, Qatar, Oman, Iraq and Kuwait.

GLI-NON-2025-00241

Leaving the Viatris site

You are leaving the Viatris site to a Viatris affiliated site or a third-party site, who is responsible for its content, including compliance with applicable guidelines in certain areas. Links to Viatris affiliated sites and third-party sites are provided as a resource to our visitors and may or may not be governed by the same regulatory requirements applicable to this site and unaffiliated third-party sites are subject to their own terms, notices and personal data protection practices. In addition, if a third-party site is subject to the laws of other countries, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided may not be appropriate for use in the Gulf markets (United Arab Emirates, Kuwait, Qatar, Oman, Bahrain and Iraq).